Which is a more important risk factor for L-DOPA-induced dyskinesia, age at onset of Parkinson's disease or age at L-DOPA treatment for Parkinson's disease?

被引：0
|
作者：
Kimura, Tamaki [1 ]
Tomiyama, Masahiko [1 ]
Arai, Akira [1 ]
Suzuki, Chieko [1 ]
Shouji, Mikio [1 ]
机构：
[1] Hirosaki Univ, Hirosaki, Aomori, Japan
来源：
NEUROSCIENCE RESEARCH | 2008年 / 61卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S203 / S203
页数：1
相关论文
共 50 条
  • [31] A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia
    Conti, Melissa M.
    Chambers, Nicole
    Bishop, Christopher
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2018, 92 : 67 - 82
  • [32] The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease
    Sara Sanz-Blasco
    Melina P. Bordone
    Ana Damianich
    Gimena Gomez
    M. Alejandra Bernardi
    Luciana Isaja
    Irene R. Taravini
    Diane P. Hanger
    M. Elena Avale
    Oscar S. Gershanik
    Juan E. Ferrario
    Molecular Neurobiology, 2018, 55 : 5125 - 5136
  • [33] l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel, Elaine
    Bortolanza, Mariza
    Dos-Santos-Pereira, Mauricio
    Bariotto, Keila
    Raisman-Vozari, Rita
    SYNAPSE, 2016, 70 (12) : 479 - 500
  • [34] The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease
    Sanz-Blasco, Sara
    Bordone, Melina P.
    Damianich, Ana
    Gomez, Gimena
    Alejandra Bernardi, M.
    Isaja, Luciana
    Taravini, Irene R.
    Hanger, Diane P.
    Elena Avale, M.
    Gershanik, Oscar S.
    Ferrario, Juan E.
    MOLECULAR NEUROBIOLOGY, 2018, 55 (06) : 5125 - 5136
  • [35] CSF catecholamine and kynurenine metabolites in Parkinson's disease and L-DOPA-induced dyskinesia
    Andersen, A. D.
    Havelund, J.
    Binzer, M.
    Blaabjerg, M.
    Kamal, A.
    Thagesen, H.
    Kjaer, T. W.
    Frgeman, N. J. K.
    Heegaard, N. H. H.
    Stenager, E.
    Gramsbergen, J. B.
    JOURNAL OF NEUROCHEMISTRY, 2017, 142 : 107 - 107
  • [36] The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease
    Vidailhet, M
    Bonnet, AM
    Marconi, R
    Durif, F
    Agid, Y
    MOVEMENT DISORDERS, 1999, 14 : 13 - 18
  • [37] Yawning as an aura for an L-dopa-induced "on" in Parkinson's disease
    Goren, JL
    Friedman, JH
    NEUROLOGY, 1998, 50 (03) : 823 - 823
  • [38] RasGRP1 is a causal factor in the development of L-DOPA-induced dyskinesia in Parkinson's disease
    Eshraghi, Mehdi
    Ramirez-Jarquin, Uri Nimrod
    Shahani, Neelam
    Nuzzo, Tommaso
    De Rosa, Arianna
    Swarnkar, Supriya
    Galli, Nicole
    Rivera, Oscar
    Tsaprailis, George
    Scharager-Tapia, Catherina
    Crynen, Gogce
    Li, Qin
    Thiolat, Marie-Laure
    Bezard, Erwan
    Usiello, Alessandro
    Subramaniam, Srinivasa
    SCIENCE ADVANCES, 2020, 6 (18):
  • [39] Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease (vol 363, 114370, 2023)
    Corsi, Sara
    Scheggi, Simona
    Pardu, Alessandra
    Braccagni, Giulia
    Caruso, Donatella
    Cioffi, Lucia
    Diviccaro, Silvia
    Gentile, Mauro
    Fanni, Silvia
    Stancampiano, Roberto
    Gambarana, Carla
    Melcangi, Roberto Cosimo
    Frau, Roberto
    Carta, Manolo
    EXPERIMENTAL NEUROLOGY, 2024, 373
  • [40] Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
    Bezard, E.
    Li, Q.
    Pioli, E.
    Crossman, A.
    MOVEMENT DISORDERS, 2019, 34 : S134 - S134
12345